Radiolabeled prostate specific membrane antigen inhibitors
US8926944B2 · kind B2 · utility
51Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2012 |
| Grant date | Jan 6, 2015 |
| Priority date | — |
| Expiry date | Sep 14, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F5/003
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity:The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.